Pagina 3 - I migliori terapisti di Terapia - TOP-151medici

Il dottor Viktor Alexander Krol dirige i dipartimenti di Gastroenterologia e Medicina Interna presso il St. Martinus-Krankenhaus di Düsseldorf, specializzandosi in trattamenti avanzati per l'obesità e i disturbi metabolici.

• Direttore di un Centro Trattamento Obesità certificato con opzioni chirurgiche ed endoscopiche
• Esperto in chirurgia bariatrica e tecniche di perdita di peso endoscopiche
• Approccio completo alle malattie gastrointestinali, cardiovascolari e respiratorie
• Utilizza metodi diagnostici e terapeutici all'avanguardia per risultati ottimali nei pazienti

Education and Expertise

Medical Education: Istanbul University, Cerrahpaşa Faculty of Medicine (1995)

Specialization: Anesthesia and Reanimation, S.B. Haydarpaşa Numune Training and Research Hospital (2000 to 2005)

Master's Degree: İstinye University, Institute of Social Sciences, Health Management (2020 to 2022)

PhD: İstinye University, Faculty of Graduate Education, Health Management (2022 to Present)

Experience

1997 to 1999 – General Practitioner, Private Marmara Hospital (Maltepe University), Cardiology Department

2005 to Present – Anesthesiology and Reanimation Clinic, S.B. Haydarpaşa Numune Training and Research Hospital

2005 to 2006 – Responsible Physician of Anesthesia and Intensive Care, Grup Universal Hospital, Kadıköy

2006 to 2012 – General Intensive Care Responsible Physician, Group Florence Nightingale Hospitals, Şişli

2012 to 2017 – General Intensive Care Responsible Physician, Grup Memorial Service Hospital

2017 to 2018 – General Intensive Care Unit, VM Medical Park Hospital, Kocaeli

2018 to Present – Responsible Manager, General Intensive Care Unit, VM Medical Park Hospital, Pendik

Professional Memberships

-Turkish Medical Association

-Turkish Anesthesiology and Reanimation Association

-Turkish Intensive Care Association

-Turkish Neurology Association

-Skull Base Association

Through rigorous training and practical experience, they have developed a deep understanding of Urology, earning recognition for their diagnostic skills and effective treatment approaches. Dr. Ahmet Tevfik Albayrak is a distinguished member of the European Society for Sexual Medicine (ESSM), a testament to their expertise and dedication in the field of sexual health. As a member of the ESSM, Dr. Ahmet Tevfik Albayrak remains connected to a network of professionals dedicated to advancing the field of sexual medicine. Their contributions to research, education, and clinical practice have earned them recognition from their peers and gratitude from the patients they serve. Furthermore, through their involvement with the ESSM, Dr. Ahmet Tevfik Albayrak stays abreast of the latest developments in sexual medicine, ensuring that they are equipped with the knowledge and skills needed to provide the highest quality of care to their patients. Their commitment to excellence and their compassionate approach to patient care continue to make a meaningful impact on the field of sexual health.

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Dr. Boaz Liberman, MD, is an orthopedic oncologist and sarcoma surgeon for adults and children. He directs the Orthopedic Oncology Unit and serves as Vice Head of Orthopedic Surgery at Sheba Medical Center. His focus is limb-sparing cancer surgery with functional reconstruction. He performs complex joint reconstruction, revision arthroplasty, MRgFUS, and reconstruction after bone metastases.

Education and training: MD, Tel Aviv University. Orthopedic surgery residency, Sheba Medical Center. Fellowships in Adult Reconstruction at Mount Sinai Hospital, Toronto, and in Orthopedic Oncology at Mount Sinai Hospital and Princess Margaret Cancer Centre. He is board-certified in Orthopedic Surgery and in Orthopedic Oncology Surgery. He is a Clinical Instructor at Tel Aviv University. Memberships include the Israel Medical Association, Israel Orthopedic Association, AATB, and EATB. He also serves on national advisory committees. His research covers bone and soft tissue sarcomas, serum markers, imaging-guided therapies, MRI arthrography, and the biomechanics of bone treated with MRgFUS.

Il medico è specialista in radiologia diagnostica e terapia minimamente invasiva, con un focus sull'ablazione a microonde dei tumori del fegato e dei polmoni sotto guida TC. Laureato all'Università Johannes-Gutenberg, il medico ha ottenuto la licenza medica nel 1988 e ha intrapreso una carriera in radiologia, diventando medico senior all'Università Ruprecht-Karls di Heidelberg. Successivamente, il medico ha servito come Medico Capo presso la Clinica Nordwest a Francoforte sul Meno ed è ora Professore Associato all'Università di Heidelberg.<\/p>

Il medico guida il centro di ablazione FUS guidato da MRI nella regione del Reno-Meno, offrendo trattamenti non chirurgici per varie condizioni. Il medico è membro onorario di DeGIR e ha ricevuto la Medaglia d'Oro di Professore Onorario dall'Università Medica di Osaka.<\/p>

Assoc. Prof. Dr. Özlem Köroğlu is a specialist in Physical Medicine and Rehabilitation at Memorial Ankara Hospital (2024–present). She previously served as a faculty member at Gaziler Physical Therapy and Rehabilitation Training and Research Hospital (2016–2024). She was Chief of the Physical Medicine and Rehabilitation Clinic at Elazığ Military Hospital (2011–2015). She earned her MD in 2003 from the GATA Faculty of Medicine. She completed her PM&R residency in 2011.

Her credentials include Ministry of Health–approved certified prolotherapy training. She has taught Prolotherapy and PRP (2022) and Knee Prolotherapy and Campinject (2019). She also taught GETAT and Dextrose Prolotherapy (2018) and ISPRM Ultrasound (2009). She has additional training in musculoskeletal ultrasound, neural therapy, lumbar injections and manipulation, and botulinum toxin treatment for the spastic hand. She attended the Euro‑Mediterranean PRM School in Italy (2010). She is a member of the Turkish Society of PM&R, the Turkish Society for Research and Fight Against Rheumatism, the Association of PM&R Specialists of Türkiye, the Spinal Cord Diseases Association, and the Ankara Medical Chamber.

Dr. Mustafa Emiroglu is a general surgery specialist at Memorial Bodrum Hospital. He has significant experience from his work at Sağlık Bilimleri University Tepecik SUAM (2016–2023) and Kırşehir Hospital (1997–1999).

He earned his medical degree from Istanbul University Cerrahpaşa Faculty of Medicine. He completed his specialization at Tepecik Training and Research Hospital. Dr. Emiroglu is a member of the Turkish Society of Surgery, the Endocrine Surgery Association, and the Colorectal Surgery Association.

He has attended advanced courses, including the Europe Senology Academia. He has also received training in proctologic, hemorrhoidal, and oncoplastic breast surgery, as well as thyroid diseases.

Patthama Likitwittaya, M.D., physiatrist. Diplomate, Thai Board of Rehabilitation Medicine (2025). Rehabilitation Medicine Residency, Faculty of Medicine, Chulalongkorn University (2025). Doctor of Medicine, First-Class Honors, Thammasat University (2019).

Current role: Department of Rehabilitation Medicine, Somdech Phra Pinklao Hospital (July 2025–present). Prior internships: Queen Sirikit Naval Hospital (2019–2020). Songkhla Naval Base Hospital (2020–2021). Naval Hospital Bangkok (2021–2022).

Research: Principal investigator of “Effect of vibrotactile stimulation on gait in Parkinson’s disease and parkinsonism.” Presented at the Royal College of Physiatrists of Thailand (2025).

Advanced training: 29th TOPF Osteoporosis and Related Diseases Grand Round (Dec 2024). Pain management with Focus Shock Wave Piezo Technology (Jul 2024). 35th TASP Annual Scientific Meeting (Mar 2024). Academic and Midyear Conferences of the Royal College of Physiatrists of Thailand (2022). Good Clinical Practice and human subject protection training (Jun 2022).

Areas of activity: • Research of pathology in gerontological age group (elderly) patients • Clinical nutrition (enteral and parenteral nutrition) • Diabetes mellitus, metabolic syndrome, osteoporosis, thyroid diseases • Arterial hypertension • High body temperature of unknown genesis (fever) • Diseases of the musculoskeletal system, rheumatological diseases • Diseases of the gastrointestinal tract, liver • Disorders of water and electrolyte metabolism, kidney diseases Education: • Higher education - Azerbaijan Medical University, Faculty of General Medicine and Prevention, 2008-2014 • Specialization – Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine Work experience: • Baku State Hospital No. 3, resident physician nephrologist. 2014-2016 • Istanbul Private Bahcelievler Memorial Hospital, specialist in internal medicine. 2021-2022 Research work: (dissertation / defense) • Clinical and laboratory features of patients with acute interstitial nephritis diagnosed during kidney biopsy, factors influencing the etiology and response to treatment. Istanbul University, Istanbul Faculty of Medicine, Department of Nephrology, 2021 Publications:(2) •P343Efficacy of adalimumab mild-to-moderate inflammatory bowel disease: Real-life data from a single-centre experience in the long-term period. January 2020 Journal of Crohns and Colitis DOI: 10.1093/ecco-jcc/jjz203.472 •Concurrent myelomatous pleural effusion and extramedullary mediastinalinvolvement as a relapse manifestation of multiple myeloma. Abstract of the IXth International Eurasian Hematology OncologyCongress17–20October2018Istanbul,Turkey(Concomitant myelomatous pleurisy and extramedullary mediastinal lesion as a recurrent manifestation of multiple myeloma. Abstracts of the IX International Eurasian Oncohematology Congress17–20October2018Istanbul,Türkiye) Memberships in scientific organizations: •Turkish Medical Association

Kultinee Klinpoon (PT) Founder & Managing Director, Sanpiti Rehabilitation Center

Ms. Kulthinee Klinpoon is the visionary founder and driving force behind Sanpiti Rehabilitation Center, one of Thailand’s leading facilities for stroke recovery and elderly care. With a strong foundation in clinical practice as a former National Team Physical Therapist and a graduate of Mahidol University, she combines medical expertise with modern business management.

Under her leadership, Sanpiti has expanded rapidly from a single center to a network of 9 branches across Bangkok and its vicinity, including strategic partnerships with premium estates like Jin Wellbeing County. Ms. Kultinee is dedicated to transforming the landscape of Thai rehabilitation by shifting the focus from "passive nursing" to "Intensive Active Rehabilitation.

Education and Expertise

• ISTANBUL UNIVERSITY FACULTY OF MEDICINE

Diseases

• Anxiety Disorder
• Bipolar Disorder
• Depression
• Obsessive Compulsive Disorders
• Panic Disorder
• Sematization
• Social Phobia
• Stress Disorder
• Schizophrenia

Treatment Methods

• Cognitive Therapy
• Individual Therapy
• Behavioral Therapy
• EMDR
• Interpersonal therapy
• Psychopharmacological
• Schema therapy

Experience

• Bakirkoy Prof. Dr. Mazhar Osman Mental and Nervous Diseases Training and Research Hospital

 Mali interdisciplinary hospital is integrating conventional, regenerative and precision medicine. It divides into 11 departments, there are 35 beds in total, including 12 intensive care beds, 23 general beds, 2 emergency and operating rooms, 1 plastic surgical room, 1 Gastro-colonoscopic room. Focus on round-trip treatment with modern medical technology to reduce the cost of hospitalization and the healing time. It also integrating regenerative medicine to repair the body and precision medicine for preventing and treating chronic non-communicable diseases (NCDs) with better results, we provide these services in a greenery atmosphere. Allowing clients to receive the following benefits.

1. Far away from NCDs & It’s complication

2. Good quality of life

3. Youthful lively life

4. Longevity

An expert in microbial resistance and optimisation of the use of antimicrobials, he leads the Infectious Disease Unit of this hospital in Malaga.

Dr Javier Moreno Izarra is habitually involved in national and international scientific events. At the same time, he gives presentations that are specially focused on infectious disease in the area of antimicrobial resistance and in medical forums dedicated to the development of programs to optimise the use of antimicrobials.

Professional Experience:

• Head of the Internal Medicine Unit. Quirónsalud Marbella Hospital

• Head of the Internal Medicine Unit. Quirón Campo de Gibraltar Hospital

• Specialist of the Internal Medicine Unit. Alto Guadalquivir Hospital

• Specialist of the Internal Medicine Unit. Andújar Hospital

• Medical Coordination of the A&E Unit and Hospitalisation. High- resolution Hospital in Puente Genil

• Specialist of the Internal Medicine Unit. Costa del Sol Hospital

A member of:

• Spanish Society of Internal Medicine

• Spanish Society of Infectious Disease and Clinical Microbiology

• Spanish Society of Palliative Care

The Internal Medicine speciality is a branch of medicine that focuses on the diagnosis, treatment and prevention of diseases and conditions of adult patients. Internists of the Quirónsalud Marbella Hospital are experts in the comprehensive health care of their patients as they manage a broad range of medical conditions. The team of specialists of our Marbella hospital stands out for its comp rehensive approach and deep knowledge and skills relating to chronic disease. Their objective is to provide a high-quality medical service while guiding the patient and coordinating the actions against their diseases in close cooperation with the other specialists, if necessary, in order to obtain an adequate diagnosis and treatment. One fundamental part of the work of an internist is the management of chronical diseases such as diabetes, hypertension, heart and lung disease, amongst others.

These conditions often require follow-ups and adjustments to the treatment throughout time.

The Internal Medicine team does not only focus on the treatment of diseases, but also on their prevention. Internists work with their patients to identify the risk factors and promote healthy habits. 

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. David (Dudi) Mishali, MD, is Director of Pediatric and Congenital Cardiothoracic Surgery at Sheba Medical Center. He treats infants and children with congenital heart defects. His work includes rare, high-risk anomalies and complex newborn reconstructions.

He trained internationally. He completed his residency at Rabin Medical Center and clinical fellowships in cardiac surgery at the Cleveland Clinic and in congenital pediatric cardiothoracic surgery at UCSF. He is board certified in cardiothoracic surgery. He developed and implemented minimally invasive methods that reduce surgical trauma and improve cosmetic results.

He is a Senior Lecturer at Tel Aviv University’s Sackler Faculty of Medicine. He has written many peer-reviewed papers and book chapters, including on point-of-care testing in children during cardiopulmonary bypass and on accessory mitral valve tissue. He holds a leadership role at a hospital ranked among the world’s top 10.

Rawipa Khunnarong, M.D. (Dr. Praew), is a physiatrist at Police General Hospital, Bangkok (2025–present). She provides rehabilitation for musculoskeletal pain, neurological disorders, and functional impairments. She works with multidisciplinary teams and teaches and supervises residents.

Education: M.D., Rangsit University/Rajavithi Hospital (2019). Rehabilitation Medicine Residency, Phramongkutklao College of Medicine (2025). Core expertise includes pain and interventional rehabilitation, neurorehabilitation (stroke, spinal cord injury), dysphagia, and sports and exercise medicine.

Advanced training includes Sports Rehabilitation Beyond Strength (2025), PMK Dry Needling (2025), and the 3rd Musculoskeletal Intervention Course (2025). She also completed a BASEM study visit (2024), Olympus FEES for dysphagia (2024), AOCNR (2023), TRMA (2022), and Viatris programs (2022–2023).